Kornimate/medical-research-clean huggingface dataset:
detection of alzheimer's disease (ad)-related seeds for ad diagnosis

Conditions: Alzheimer's Disease

Summary: the study will investigate the biomarkers of aβ and tau seeds in plasma detected by alzheimer's disease (ad) related seeds quantitative detector (ad-seeds-detector), and their sensitivity and specificity in diagnosing ad, compared with those from age-matched cognitively normal controls, and those with other types of dementia. to perform a high throughput analysis of the amount of aβ and tau seeds, the investigators have developed an ad-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.

aβ and tau seeds have the potential to serve as biomarkers for ad. the ad-seeds-detector could detect small quantities of aβ and tau seeds by taking advantage of their ability to nucleate and enhance aggregation, enabling a very high amplification of the signal. this study examines the effectiveness of using the ad-seeds-detector as a novel technique for discriminating ad from cognitively normal control and non-ad dementia by detecting small aβ and tau seeds in plasma. this will be an observational study aiming at using the ad-seeds-detector to detect minute amounts of aβ and tau seeds in plasma as novel biomarkers with high sensitivity and specificity for the accurate diagnosis of ad. to achieve this goal, the investigators will conduct two studies using the ad-seeds-detector to detect the aβ and tau seeds in the plasma samples. study one: a single-center cohort that consists of well-characterized ad patients (n=150), cognitively normal controls (n=100) and non-ad dementia patients (n=50). study two: a multi-center cohort with well-characterized ad patients (n=400), cognitively normal controls (n=400) and non-ad dementia patients (n=400).

Eligibility criteria:
inclusion criteria: * aged 55-75. written informed consent obtained from participant or legal guardian prior to any study-related procedures. the diagnosis of ad is made using the national institute on aging and the alzheimer's association (nia-aa) criteria. as for non-ad dementia, the mckeith criteria are used for dlb,the revised diagnostic criteria proposed by the international behavioral variant (bvftd) criteria consortium for bvftd,the gorno-tempini criteria for the semantic variant ftd or non-fluent aphasia, the movement disorder society task force criteria for pdd, the vascular behavioral and cognitive disorders (vas-cog) criteria for vad, the armstrong's criteria for cbd, the cdc's diagnostic criteria for cjd, etc. in addition, normal cognition is supported by mmse, cdr and other cognitive function scales. exclusion criteria: * other medical or psychiatric illness. no one can serve as an informant. refused to complete a cognitive test and provide biospecimen.

Keywords: alzheimer's disease
could single-anastomosis gastric bypass be a curative treatment for type ii diabetes?

Conditions: Metabolic Surgery

Summary: single- anastomosis gastric bypass (sagb) is a potentially curative line of treatment for type ii diabetes mellitus (t2dm) patients with bmi 25-30 kg/m2. accordingly, sagb could be integrated into t2dm treatment algorithm

background: t2dm has been considered as a chronic progressive incurable metabolic disease. single-anastomosis gastric bypass (sagb) was shown to be effective in obese patients in terms of weight reduction and t2dm remission, yet its effect on non-obese diabetics is not extensively studied. in this study, we tried to determine the anthropometric and glycemic outcomes of sagb as a proposed line of treatment for type ii diabetes mellitus (t2dm) patients with body mass index (bmi) 25-30 kg/m2. methods: from november 2013 to march 2016, a prospective study has been conducted at ain-shams university hospitals on 17 consecutive patients undergone sagb. the demographic and anthropometric data of the patients, as well as their relevant laboratory results, were reported, other data including anti-diabetic medications, co-morbid metabolic diseases were also assessed. all patients were scheduled for laparoscopic sagb and were advised to come in regular follow up at 1, 3, 6, 12 and 18 months postoperatively. t2dm remission is considered if glycosylated hemoglobin (hba1c) \<6.5 % and fasting plasma glucose (fpg) \< 126 mg/dl for at least 1 year without medication.

Eligibility criteria:
inclusion criteria: .type ii diabetic patients. * age: 20-60 years. * either gender. exclusion criteria: * previous bariatric surgery. * controlled t2dm. * duration of t2dm \>10 years. * patients with endocrinal diseases, * pregnancy. * those unfit for general anesthesia.

Keywords: metabolic surgery, bmi 25-30 kg/m2, sagb, t2dm remission.
augmented multimodal neurologic monitoring in high risk survivors of cardiac arrest

Conditions: Cardiac Arrest

Summary: cardiac arrest is the most common cause of death in the united states and as many as 590,000 americans suffering a cardiac arrest each year. despite advances in care, as many as 50 to 89% of patients who are resuscitated after a cardiac arrest die in the hospital. brain injury is the most common cause of death and disability after cardiac arrest. the investigators use advanced brain monitoring in patients who are at high risk of death after cardiac arrest, with the goal of preventing ongoing brain injury. the most common problem the investigators have observed is low oxygen levels in the brain, which is often very difficult to treat. in this study, the investigators plan to use two additional brain monitors in the care of these high risk patients: a monitor for seizures and a monitor of the amount of blood flow in the brain. the investigators will use these to detect and treat potential causes of low brain oxygen levels. the main hypotheses are that electrical events in the brain such as seizures and "spreading depolarizations" will occur during times of low brain tissue oxygen level, and that treating these events and low blood flow will reduce the rate of low brain oxygen levels.


Eligibility criteria:
inclusion criteria: * high risk survivors of cardiac arrest * decision by potential subject's clinical team to use our institutional standard invasive, multimodal neurologic monitoring for post-arrest care exclusion criteria: * none

Keywords: cardiac arrest neurological injury seizures spreading depolarizations cerebral hypoperfusion brain tissue hypoxia
interest of bone substitute material in immediate complete denture

Conditions: Alveolar Bone Loss; Denture Complete Immediate; Bone Substitute; Replacement Material; Bone

Summary: more than 2 million french people suffer from the widespread disability of edentulism, with large consequences on function, nutrition, aesthetics and well-being. complete denture is a common therapeutic strategy. the immediate complete denture technique consists in placing the denture in the same clinical session as last anterior teeth extractions. with this technique, aesthetic and function are immediately reintroduced and the patient is never left toothless or without any denture. after teeth extractions, alveolar healing process leads to ridge resorption with bone volume modifications and reduction in height and width. however ridge bone volume is an essential factor in removable denture stability. with implantology as an alternative prosthetic strategy, ridge volume is also a most important factor to place dental implants in a situation close to previous dental roots position. in order to preserve bone volume, a current alternative strategy proposes to place bone substitute materials in tooth sockets after extraction. this strategy was never evaluated with the immediate complete denture technique. hypothesis: a new strategy associating immediate complete denture and bone substitute material is more effective than conventional immediate complete denture in a bone preservation perspective.


Eligibility criteria:
inclusion criteria: * candidates for maxillary immediate complete denture, presenting a kennedy * class i partial dentition (bilateral posterior tooth loss) * over 18 years of age * healthy adhering gingiva * willing to participate in the study, able to sign the consent form exclusion criteria: - medical conditions contraindicating oral surgery: progressive cancer history of radiotherapy in the head and neck region major neurological disease anti-coagulant treatment with prothrombin time\<30% valvulopathy, hematologic disease, agranulocytosis, serious heart failure, recent myocardial infarction \< 5 years immune deficiency, aides osteomalacia hepatic or renal insufficiency unregulated diabetes long-term steroids treatment bisphosphonates * allergy to collagen * pregnant or nursing women * persons specially protected * non-affiliated with the social security system persons

Keywords: immediate complete denture alveolar ridge resorption alveolar bone loss bone substitute material edentulism
creation of a syncope channel for patients admitted to the emergency department for loss of consciousness and not hospitalized: etiological predictivity (before/after study)

Conditions: Syncope

Summary: the main aim of this study is to assess the value of creating a "syncope pathway" to optimize diagnostic performance in patients admitted to the emergency department for syncope and not hospitalized, compared with the previous pre-syncope pathway situation.


Eligibility criteria:
inclusion criteria: * adults aged 18 and over; * consultant at the emergency department of the centre hospitalier de v ersailles * for a confirmed diagnosis: * of recurrent syncope with low-risk criteria according to esc 2018 (1,2) or * of syncope recurrent or not, not fulfilling low-risk or high-risk criteria according to the esc 2018 definition (1,2). these patients are those with minor high-risk criteria without aggravating circumstances: * with no personal history of loss of consciousness whose clinical features strongly suggest syncope of rhythmic origin; * no structural heart disease or abnormal ecg. * outpatient (returning home after emergency); * beneficiary or beneficiary of a social security scheme (excluding ame). exclusion criteria: * etiology of syncope identified as early as the emergency department visit; * high-risk syncope according to esc 2018 criteria (1,3); * first and only episode of low-risk syncope according to esc 2018 criteria (1,3); * syncope of any risk category requiring hospitalization at the discretion of the emergency physician and cardiologist; * legal protection by guardianship ; * language barrier or condition incompatible with the patient's understanding or informed adherence to the protocol; * opposition to the use of their pseudonymized data (for retrospective inclusions); * patient's refusal to give consent to participate in the study (for prospective inclusions);
evaluation of rgh therapy to prevent muscle atrophy in patients with acl tears

Conditions: Rupture of Anterior Cruciate Ligament

Summary: anterior cruciate ligament (acl) tears are among the most frequent traumatic knee injuries that occur in physically active individuals. despite advances in minimally invasive surgical reconstruction techniques and aggressive rehabilitation, this atrophy and loss of strength can persist even after patients return to full activity and can place them at considerable risk for re-injury and developing osteoarthritis (oa). the design of new therapeutic interventions to prevent muscle atrophy is needed to advance the care of patients who suffer from acl injuries. the growth hormone (gh)/insulin-like growth factor-1 (igf-1) axis plays an important role in promoting muscle growth and protecting muscle from atrophy. while gh therapy has shown promise in protecting immobilized muscle from various models of disuse atrophy, it remains unknown whether gh can help to restore strength and protect against the loss in strength that occurs after acl tear. gh therapy may help to accelerate the safe return to play of patients that suffer acl tears, and help to prevent the long-term oa and reduction in quality of life that occur after these traumatic knee injuries.


Eligibility criteria:
inclusion criteria: * males between the ages of 18 and 35 * have acute unilateral complete acl tears with or without bucket handle medial meniscus tears that occurred within the past 6 months * consent to undergo an acl reconstruction by an orthopaedic surgeon using a patellar tendon or hamstring autograft * will be performing supervised post-operative rehabilitation at umhs medsport at dominos farms exclusion criteria: * patients who are undergoing a revision acl reconstruction * had a previous injury to the involved knee * have an allergy to recombinant gh * have a bmi\ 35 * have a growth disorder of bones or connective tissue, type 1 diabetes mellitus, type 2 diabetes mellitus, or who have a history of carpal tunnel syndrome, trigger finger, myopathy, cancer, endocrine disorder, hypertension or rheumatologic disorder. * systolic blood pressure \>140mm hg or diastolic blood pressure \>90mm hg, or with resting heart rate \>110 bpm or \<40 bpm at screening. * additionally, because gh is currently listed as a banned substance by the world anti-doping agency (wada), national collegiate athletics association (ncaa) and most professional sports agencies, we will exclude patients who are current collegiate, professional or elite athletes.

Keywords: muscle atrophy growth hormone acl tear
a psychological intervention to promote acceptance and adherence to niv in people with copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study aims to analyze the impact of a brief psychological support intervention in the promotion of the adherence to non invasive ventilation (niv) among people with chronic obstructive pulmonary disease (copd). the investigators expect to see a positive impact of this intervention on both physical and psychological well-being, and consequently, a reduction of health costs.


Eligibility criteria:
inclusion criteria: * age\> or =18 years * the voluntary participation to the study * inpatients or outpatients * subjects with chronic obstructive pulmonary disease (copd), from moderate (gold 2- 50% ≤ fev1 \<80% pred.) to severe (gold 3- 30% ≤ fev1 \<50%pred.) (fev1= forced expiratory volume in the 1st second) exclusion criteria: * refusal of the informant consent * pregnancy * subjects affected by oncological or psychiatric illnesses * immune depressive condition as the principal condition * usage of antidepressant drugs

Keywords: chronic obstructive pulmonary disease (copd) non invasive ventilation (niv) acceptance adherence clinical psychology
immunoscintigraphy using radiolabeled monoclonal antibody in finding tumor cells in patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: diagnostic procedures, such as immunoscintigraphy, using a radiolabeled monoclonal antibody may help find and diagnose colorectal cancer. purpose: this clinical trial is studying how well immunoscintigraphy using a radiolabeled monoclonal antibody works in finding tumor cells in patients with colorectal cancer.

objectives: primary * to determine the ability of iodine i 123 anti-cea recombinant diabody t84.66 to localize to colorectal cancer, as determined by quantitative radioimmunoscintigraphy in patients with colorectal cancer. secondary * to evaluate the clinical pharmacokinetics of iodine i 123 anti-cea recombinant diabody t84.66 clearance in these patients. * to characterize the frequency and titer of the human anti-chimeric response to iodine i 123 anti-cea recombinant diabody t84.66 in these patients. * to determine the safety of iodine i 123 anti-cea recombinant diabody t84.66 in these patients. outline: patients receive an infusion of iodine i 123 anti-cea recombinant diabody t84.66. patients undergo planar imaging every 5 minutes during the radiolabeled antibody infusion and then at 3-6 hrs, 12-24 hours, and, if indicated, 30-48 hours after the radiolabeled antibody infusion. planar spot images of the head, chest, abdomen, and pelvis and whole body images (anterior and posterior) are taken. patients also undergo spect scan of the abdomen and pelvis at 12 and 24 hours after the radiolabeled antibody infusion. blood samples are collected for pharmacokinetic analysis immediately after the radiolabeled antibody infusion and then at 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours after the radiolabeled antibody infusion. patients are followed periodically for 6 months.

Eligibility criteria:
disease characteristics: * histologically confirmed colorectal cancer * stage i-iv disease patient characteristics: * serum creatinine \< 2.0 mg/dl * total bilirubin \< 2.0 mg/dl * hemoglobin \> 9.0 g/dl * ct84.66 antibody negative (if previously treated with mouse or chimeric immunoglobulins) * not pregnant * no condition that, in the opinion of the investigator, would preclude study compliance * no known allergy to iodine * no known history of hiv, hepatitis b, or hepatitis c prior concurrent therapy: * no concurrent steroids

Keywords: stage i colon cancer stage ii colon cancer stage iii colon cancer stage iv colon cancer stage i rectal cancer stage ii rectal cancer stage iii rectal cancer stage iv rectal cancer
chronic pain in rheumatoid arthritis

Conditions: Arthritis, Rheumatoid; Pain

Summary: the objective is to identify modifiable clinical factors and neurobiological pathways that lead to the development of chronic pain in patients with early rheumatoid arthritis. participants will undergo quantitative sensory testing, a type of testing that involves assessing response to well-defined, quantifiable painful stimuli, at 0, 3, and 12 months. a subset of participants will also undergo magnetic resonance imaging at 0 and 12 months to assess neuroimaging markers that have previously been shown to be involved in chronic pain.


Eligibility criteria:
inclusion criteria for qst: 1. age ≥18 years 2. meet either the 1987 or 2010 american college of rheumatology (acr)/european league against rheumatism (eular) criteria for ra 3. persistent joint symptoms ≤ 2 years 4. active inflammatory disease 5. if taking opioids on an as needed (prn) basis, must be able to hold opioid for 12 hours before study procedures 6. if taking nsaids, must be able to hold nsaids for 24 hours before study procedures 7. if taking a central-acting pain medication, must be on a stable dose and able to stay on a stable dose throughout study exclusion criteria for qst: 1. routine, scheduled opioid use 2. routine, scheduled prednisone dose \>10 mg or its equivalent 3. peripheral neuropathy 4. peripheral vascular disease 5. raynaud's phenomenon requiring treatment, manifested by claudication or ischemic rest pain 6. uncontrolled blood pressure additional inclusion criteria for neuroimaging: 1. age ≤ 80 years old 2. right-handed or ambidextrous 3. ability to lie on their back for the duration of the mri scans additional exclusion criteria for neuroimaging: 1. severe claustrophobia precluding mri 2. unable to fit comfortably in the mri scanner (usually only occurs if body mass index \>40 kg/m2) 3. pregnant 4. contraindications to mri
safety and efficacy study of fingolimod in taiwanese adults (≥ 20years) with relapsing remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of the study is to describe the safety profile of fingolimod in the taiwanese multiple sclerosis population. this study aims to collect the safety data in patients newly initiated on fingolimod for one year.

this is a 12-month, prospective, interventional, multi-center study to monitor safety in adult patients with relapsing-remitting multiple sclerosis (rrms) in taiwan who based on local practice are newly starting fingolimod at the time of study entry. thirty-four patients will be included in this study in line with the study inclusion and exclusion criteria. after entering this study, the participants will continue to be treated for ms based on local practice. the patient will be taking fingolimod 0.5mg per day. protocol-mandated procedures and visits for safety data collection will be conducted in addition to the required examinations according to the clinical practice. if a patient experienced an interruption of fingolimod treatment that requires a re-evaluation of fdo, the patient will be discontinued from the study. if the treatment interruption does not require a fdo when re-starting fingolimod, the patient can continue to participate in this study.

Eligibility criteria:
inclusion criteria: -patients with relapsing-remitting multiple sclerosis that are fingolimod treatment naive at the time of study entry and are newly starting fingolimod based on physician judgement and according to taiwan's fingolimod package insert (version twi-090420) exclusion criteria: * patients with the diagnosis of neuromyelitis optica. * patients who are being treated with any investigational drug at the time of study entry. * in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization or class iii/iv heart failure * a history or presence of mobitz type ii second-degree or third-degree atrioventricular block or sick sinus syndrome, unless patient has a functioning pacemaker * a baseline qtc interval ≥ 500 msec * cardiac arrhythmias requiring anti-arrhythmic treatment with class ia or class iii anti-arrhythmic drugs * patient with known immune deficiency, increased risk of opportunistic infection, severe active infection or chronic active infection. * patients with severe active malignancies, except for basal cell epithelioma * patients with severe hepatic insufficiency * pregnant or nursing (lactating) women or women of childbearing potential unless on contraception

Keywords: fingolimod multiple sclerosis relapsing-remitting multiple sclerosis relapsing-remitting post-authorization study adult ms
treatment of periodontitis using er:yag laser vs. conventional treatment modalities

Conditions: Chronic Periodontitis

Summary: conventional non-surgical periodontal treatment, that is, root debridement using manual and ultrasonic means at baseline and surgery using the same means after 6 months in case of persistent deep pockets (group 1)/ er:yag laser used in a non-surgical approach at baseline and surgery using the same laser after 6 months in case of persistent deep pockets (group 2)/ surgery at baseline using manual and ultrasonic means (group 3). all patients will undergo supragingival maintenance on a yearly basis.


Eligibility criteria:
inclusion criteria: * at least 35 years of age * at least 18 teeth present that can be retained by means of therapy among which 4 multirooted teeth or more(wisdom teeth excluded) * presence of at least one deep pocket per quadrant (6 mm ppd or more) with radiographic evidence of bone loss (\>= 30% of root length) exclusion criteria: * pregnancy * removable prosthesis